查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
Fc 和糖工程抗體市場 – 按工程類型、治療類型、治療領域、給藥途徑、關鍵地區：產業趨勢和全球預測
市場調查報告書
商品編碼
1471916

Fc 和糖工程抗體市場 – 按工程類型、治療類型、治療領域、給藥途徑、關鍵地區：產業趨勢和全球預測

Fc and Glycoengineered Antibodies Market - Distribution by Type of Engineering, Type of Therapy, Therapeutic Area, Route of Administration and Key Geographical Regions : Industry Trends and Global Forecasts
出版日期: | 出版商: Roots Analysis | 英文 293 Pages | 商品交期: 最快1-2個工作天內

價格

2024年Fc和糖工程抗體市場規模預估為388億美元，2024-2035年預測期間複合年增長率為5.86%。

基於抗體的藥理幹預已成為生物製藥行業增長最快的領域之一，已批准的單株抗體數量超過了驚人的 120 種，並且有近 900 項註冊臨床試驗。 這個快速成長的產業對全球銷售額做出了巨大貢獻，預計到 2025 年將超過 3,000 億美元，並在醫療保健領域發揮至關重要的作用。 藥物的治療功效，定義為在治療特定疾病時產生所需治療效果的能力，是最重要的考慮因素。 具有高療效的藥物可透過提高標靶特異性、減少副作用和延長藥物半衰期來改善治療結果。 最近開發了各種 Fc 和糖工程策略來增強抗體的治療功效。

Fc工程是一種修飾抗體Fc區以改善抗體依賴性細胞毒性（ADCC）、抗體依賴性細胞吞噬作用（ADCP）和補體依賴性細胞毒性（CDC）等效應子的技術。 。 相反，糖工程透過控制分子內的聚醣組成來優化治療性抗體的藥物動力學和藥效學特性。 這些工程抗體被廣泛用於增強單株抗體的抗腫瘤功效。 目前，許多藥物開發公司和技術提供者正在積極致力於該領域各種Fc抗體和糖工程抗體的開發。 此外，幾家主要製藥公司對這些工程抗體表現出了濃厚的興趣，並在時間和資本方面投入了大量資源到 Fc 和糖工程抗體市場。 目前，超過 150 種 Fc 和糖工程抗體已獲得全球批准，最近（2023 年）的著名例子包括 retifanlimab、erlanatamab、grofitamab 和 tislizumab。

在前景光明的抗體藥物管道、持續的技術進步以及生物製藥開發商日益增長的興趣的推動下，Fc 和糖工程抗體市場預計將在預測期內出現顯著增長。 這個快速發展的領域具有改善治療結果和推動個人化醫療前沿的巨大潛力。

本報告調查了全球 Fc 和糖工程抗體市場，提供了市場概述、工程類型、治療類型、治療領域、給藥途徑、區域和市場進入的趨勢。

目錄

第1章前言

第2章研究方法

第 3 章經濟與其他專案特定考量

第 4 章執行摘要

第 5 章簡介

  • 章節概述
  • 抗體結構
  • 抗體開發的歷史時間表
  • 抗體同種型
  • 抗體的作用機制
  • Fc 區和效應器功能
  • 未來前景

第6章市場狀況

  • 章節概述
  • Fc 和醣工程抗體：整體研發管線
  • Fc 和糖工程抗體：開發商的整體情況

第7章公司簡介

第8章臨床試驗分析

  • 章節概述
  • 範圍與研究方法
  • Fc 和糖工程抗體：臨床試驗分析

第 9 章夥伴關係與協作

  • 章節概述
  • 合作夥伴模式
  • Fc 與糖工程抗體：夥伴關係與協作

第 10 章撥款分析

第11章專利分析

第12章全球 Fc 與糖工程抗體市場

第 13 章 Fc 和糖工程抗體市場（依工程類型）

第 14 章 Fc 和糖工程抗體市場（依治療類型）

第 15 章 Fc 與糖工程抗體市場（依治療領域）

第 16 章 Fc 和糖工程抗體市場（依給藥途徑）

第 17 章 Fc 和糖工程抗體市場（按主要地區）

第18章 Fc 和糖工程抗體市場，藥品銷售預測

第19章結論

第 20 章附錄一：表格資料

第 21 章附錄二：公司與組織名單

Product Code: RA100489

The Fc and glycoengineered antibodies market is valued at USD 38.8 billion in 2024 growing at a CAGR of 5.86% during the forecast period 2024-2035.

Antibody-based pharmacological interventions have emerged as one of the fastest-growing segments within the biopharmaceutical industry, with a staggering number of approved monoclonal antibodies exceeding 120, and nearly 900 registered clinical trials for evaluation. This burgeoning field is projected to contribute significantly to global sales, surpassing USD 300 billion by 2025, underscoring its pivotal role in the healthcare landscape. The therapeutic efficacy of a drug, defined as its ability to produce the desired therapeutic effects in treating a particular disease, is a paramount consideration. A drug with high therapeutic efficacy offers improved treatment outcomes by increasing target specificity, reducing side effects, and extending the drug's half-life. To enhance the therapeutic efficacy of antibodies, various Fc and glycoengineering strategies have been developed recently.

Fc engineering focuses on modifying the Fc regions of antibodies to enhance their effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), thereby increasing the molecule's half-life. Conversely, glycoengineering optimizes the pharmacokinetic and pharmacodynamic properties of therapeutic antibodies by controlling the glycan composition within the molecule. These engineered antibodies are widely utilized in enhancing the anti-tumor potential of monoclonal antibodies. Currently, numerous drug developers and technology providers in this domain are actively engaged in developing various Fc and glycoengineered antibodies. Additionally, several major pharmaceutical companies have demonstrated a keen interest in these engineered antibodies, investing substantial resources in terms of time and capital into the Fc and glycoengineered antibodies market. Presently, over 150 Fc and glycoengineered antibodies have received global approval, with notable recent examples (in 2023) including Retifanlimab, Elranatamab, Glofitamab, and Tislelizumab.

Driven by the promising antibody-based drug pipeline, ongoing technical advancements, and the growing interest of biopharmaceutical developers, the Fc and glycoengineered antibodies market is poised to witness remarkable growth during the forecast period. This burgeoning field holds immense potential for improving therapeutic outcomes and advancing the frontiers of personalized medicine.

Key Market Segments

Type of Engineering

  • Fc Engineered Antibodies
  • Glycoengineered Antibodies

Type of Therapy

  • Monotherapy
  • Combination Therapy
  • Both

Therapeutic Area

  • Autoimmune Disorders
  • Dermatological Disorders
  • Oncological Disorders
  • Rare Diseases
  • Other Disorders

Route of Administration

  • Intravenous Route
  • Subcutaneous Route
  • Intramuscular Route

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the Fc and glycoengineered antibodies market based on type of engineering, type of therapy, therapeutic area, route of administration, and key geographical regions
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to five major regions
  • A general overview of antibodies, including structure, historical discovery timeline, isotypes, and mechanisms of action. Brief overview of Fc region, effector functions, Fc receptor types, engineering (glycoengineering, protein engineering, isotype chimerism), and future growth perspectives.
  • Detailed assessment of over 170 marketed/development antibody programs for various indications. Analysis based on development phase, antibody type, engineering type, impact, target, therapy type, disease indication, therapeutic area, administration route, and popular Fc engineering technologies.
  • Elaborate profiles of prominent Fc-engineered antibody developers, including company overview, financials, drug portfolio, recent developments, and future outlook.
  • In-depth analysis of completed, ongoing, and planned clinical trials of Fc and glycoengineered antibodies based on trial parameters like registration year, status, phase, patient population, sponsor type, active players, study design, indication, and geography.
  • Detailed analysis of partnerships since 2016 based on year, type, engineering type, therapeutic area, active players, and regional distribution.
  • Analysis of grants (2019-2024) for Fc/glycoengineered antibody projects based on award year, amount, funding source, period, application type, purpose, activity code, study section, NIH departments, program officers, and recipient organizations.
  • Elaborate patent analysis covering types, years, applicant types, geographies, CPC symbols, active players, benchmarking, and valuation of leading patents by citations.
  • Detailed 2024-2035 market forecast estimating current size and future opportunity based on engineering types, therapy types, therapeutic areas, administration routes, key regions, and revenues from marketed/phase III drugs.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Fc and glycoengineered antibodies market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • AbbVie
  • Akesobio
  • Alexion Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Genentech
  • MacroGenics
  • MorphoSys
  • Kyowa Kirin
  • Xencor

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2 RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Considerations
    • 2.6.1. Demographics
    • 2.6.2. Economic Factors
    • 2.6.3. Government Regulations
    • 2.6.4. Supply Chain
    • 2.6.5. COVID Impact / Related Factors
    • 2.6.6. Market Access
    • 2.6.7. Healthcare Policies
    • 2.6.8. Industry Consolidation
  • 2.7. Key Market Segmentations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
      • 3.2.2.3. Foreign Exchange Impact
      • 3.2.2.4. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.2.5. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.3. Recession
      • 3.2.3.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.3.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.4. Inflation
      • 3.4.4.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.4.4.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

  • 4.1. Chapter Overview

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Structure of Antibodies
  • 5.3. Historical Timeline of Antibody Development
  • 5.4. Antibody Isotypes
  • 5.5. Mechanism of Action of Antibodies
  • 5.6. Fc Region and Effector Functions
    • 5.6.1. Types of Fc Receptors
    • 5.6.2. Engineering of the Fc Region
      • 5.6.2.1. Glycoengineering
      • 5.6.2.2. Protein Engineering
      • 5.6.2.3. Isotype Chimerism
  • 5.7. Future Perspective

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Fc Engineered and Glycoengineered Antibodies: Overall Pipeline
    • 6.2.1. Analysis by Stage of Development
    • 6.2.2. Analysis by Type of Antibody
    • 6.2.3. Analysis by Type of Engineering
    • 6.2.4. Analysis by Impact of Engineering
    • 6.2.5. Analysis by Biological Target
    • 6.2.6. Analysis by Type of Therapy
    • 6.2.7. Analysis by Target Disease Indication
    • 6.2.8. Analysis by Therapeutic Area
    • 6.2.9. Analysis by Route of Administration
    • 6.2.10. Popular Fc Engineering Technologies: Analysis by Number of Marketed Drugs and Development Programs
  • 6.3. Fc Engineered and Glycoengineered Antibodies: Overall Developer Landscape
    • 6.3.1 Analysis by Year of Establishment
    • 6.3.2 Analysis by Company Size
    • 6.3.3 Analysis by Location of Headquarters
    • 6.3.4. Leading Developers: Analysis by Number of Drugs

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Detailed Company Profiles of Leading Fc Engineered and Glycoengineered Antibody Drug Developers
    • 7.2.1. AbbVie
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Financial Information
      • 7.2.1.3. Drug Portfolio
        • 7.2.1.3.1. Drug Profile: Skyrizi
      • 7.2.1.4. Recent Developments and Future Outlook
    • 7.2.2. Alexion Pharmaceuticals
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Drug Portfolio
        • 7.2.2.2.1. Drug Profile: Soliris
        • 7.2.2.2.2. Drug Profile: Ultomiris
      • 7.2.2.3. Recent Developments and Future Outlook
    • 7.2.3. AstraZeneca
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Financial Information
      • 7.2.3.3. Drug Portfolio
        • 7.2.3.3.1. Drug Profile: Beyfortus
        • 7.2.3.3.2. Drug Profile: Imfinzi
        • 7.2.3.3.3. Drug Profile: Fasenra
        • 7.2.3.3.4. Drug Profile: Saphnelo
      • 7.2.3.4. Recent Developments and Future Outlook
    • 7.2.4. Genentech
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Financial Information
      • 7.2.4.3. Drug Portfolio
        • 7.2.4.3.1. Drug Profile: Gazyva
        • 7.2.4.3.2. Drug Profile: Ocrevus
        • 7.2.4.3.3. Drug Profile: Tecentriq
      • 7.2.4.4. Recent Developments and Future Outlook
    • 7.2.5. MacroGenics
      • 7.2.5.1. Company Overview
      • 7.2.5.2. Financial Information
      • 7.2.5.3. Drug Portfolio
        • 7.2.5.3.1. Drug Profile: Margenza
        • 7.2.5.3.2. Drug Profile: MGA-271
      • 7.2.5.4. Recent Developments and Future Outlook
    • 7.2.6. Kyowa Kirin
      • 7.2.6.1. Company Overview
      • 7.2.6.2. Financial Information
      • 7.2.6.3. Drug Portfolio
        • 7.2.6.3.1. Drug Profile: POTELIGEO
      • 7.2.6.4. Recent Developments and Future Outlook
  • 7.3. Short Company Profiles of Leading Fc Engineered and Glycoengineered Antibody Drug Developers
    • 7.3.1. Akeso Biopharma
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Drug Portfolio
        • 7.3.1.2.1. Drug Profile: Penpulimab
    • 7.3.2. Amgen
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Drug Portfolio
        • 7.3.2.2.1. Drug Profile: Bemarituzuman
        • 7.3.2.2.2. Drug Profile: STEAP1 XmAb Antibody
        • 7.3.2.2.3. Drug Profile: FPA157
    • 7.3.3. Boehringer Ingelheim
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Drug Portfolio
        • 7.3.3.2.2. Drug Profile: Spesolimab
    • 7.3.4. MorphoSys
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Drug Portfolio
        • 7.3.4.2.1. Drug Portfolio: Tafasitamab
    • 7.3.5. Xemcor
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Drug Portfolio
        • 7.3.5.2.1. Drug Portfolio: Tidutamab
        • 7.3.5.2.2. Drug Portfolio: XmAb22841
        • 7.3.5.2.3. Drug Portfolio: XmAb23104
        • 7.3.5.2.4. Drug Portfolio: Plamotamab
        • 7.3.5.2.5. Drug Portfolio: Vibecotamab
        • 7.3.5.2.6. Drug Portfolio: RO7310729
        • 7.3.5.2.7. Drug Portfolio: XmAb20717
        • 7.3.5.2.8. Drug Portfolio: XmAb819
        • 7.3.5.2.9. Drug Portfolio: XmAb27564
        • 7.3.5.2.10. Drug Portfolio: VRC01LS

8. CLINICAL TRIAL ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Fc Engineered and Glycoengineered Antibodies: Clinical Trial Analysis
    • 8.3.1. Analysis by Trial Registration Year
    • 8.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
    • 8.3.3. Analysis by Trial Phase
    • 8.3.4. Analysis of Number of Patients Enrolled by Trial Phase
    • 8.3.5. Analysis by Trial Registration Year and Trial Phase
    • 8.3.6. Analysis by Trial Status
    • 8.3.7. Analysis by Patient Gender
    • 8.3.8. Analysis by Target Indication
    • 8.3.9. Analysis by Study Design
      • 8.3.9.1. Analysis by Type of Trial Masking
      • 8.3.9.2. Analysis by Type of Intervention Model
      • 8.3.9.3. Analysis by Type of Trial Purpose
      • 8.3.9.4. Analysis by Design Allocation
    • 8.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
      • 8.3.10.1. Analysis by Leading Industry Players
      • 8.3.10.2. Analysis by Leading Non-Industry Players
    • 8.3.11. Analysis by Geography
      • 8.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
      • 8.3.11.2. Analysis of Patients Enrolled by Trial Status and Geography

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Fc Engineered and Glycoengineered Antibodies: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Engineering
    • 9.3.5. Analysis by Therapeutic Area
    • 9.3.6. Most Active Players: Analysis by Number of Partnerships
    • 9.3.7. Analysis by Geography
      • 9.3.7.1. Intracontinental and Intercontinental Agreements
      • 9.3.7.2. Local and International Agreements

10. GRANT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Fc Engineered and Glycoengineered Antibodies: Grant Analysis
    • 10.3.1. Analysis by Year of Grant Award
    • 10.3.2. Analysis by Amount Awarded
    • 10.3.3. Analysis by Funding Institute Center
    • 10.3.4. Analysis by Support Period
    • 10.3.5. Analysis by Funding Institute Center and Support Period
    • 10.3.6. Analysis by Type of Grant Application
    • 10.3.7. Analysis by Purpose of Grant Award
    • 10.3.8. Analysis by Activity Code
    • 10.3.9. Analysis by Study Section Involved
    • 10.3.10. Most Popular NIH Departments: Analysis by Number of Grants
      • 10.3.10.1. Prominent Program Officers: Analysis By Number of Grants
      • 10.3.10.2. Popular Recipient Organizations: Analysis by Number of Grants
      • 10.3.10.3. Popular Recipient Organizations: Analysis by Grant Amount
    • 10.3.11. Popular Recipient Organizations: Distribution by States in the US

11. PATENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Fc Engineered and Glycoengineered Antibodies: Patent Analysis
    • 11.3.1. Analysis by Patent Publication Year
    • 11.3.2. Analysis by Patent Application Year
    • 11.3.3. Analysis by Granted Patents and Patent Applications, 2019-2023
    • 11.3.4. Analysis by Patent Jurisdiction
    • 11.3.5. Analysis by CPC Symbols
    • 11.3.6. Analysis by Type of Applicant
    • 11.3.7. Leading Industry Players: Analysis by Number of Patents
    • 11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 11.3.9. Leading Patent Assignees: Analysis by Number of Patents
    • 11.3.10. Patent Benchmarking Analysis
      • 11.3.10.1. Analysis by Patent Characteristics
    • 11.3.11. Patent Valuation
    • 11.3.12. Leading Patents by Number of Citations

12. GLOBAL Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Methodology
  • 12.3. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035)
    • 12.3.1. Scenario Analysis
      • 12.3.1.1. Conservative Scenario
      • 12.3.1.2. Optimistic Scenario
  • 12.4. Key Market Segmentations

13. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY TYPE OF ENGINEERING

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering, 2024 and 2035
    • 13.3.1. Fc Engineered Antibodies Market, 2024-2035
    • 13.3.2. Glycoengineered Antibodies Market, 2024-2035
  • 13.4. Data Triangulation and Validation

14. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY TYPE OF THERAPY

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035
    • 14.3.1. Fc Engineered and Glycoengineered Market for Monotherapy, 2024-2035
    • 14.3.2. Fc Engineered and Glycoengineered Market for Combination Therapy, 2024-2035
    • 14.3.3. Fc Engineered and Glycoengineered Market for Both, 2024-2035
  • 14.4. Data Triangulation and Validation

15. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY THERAPEUTIC AREA

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035
    • 15.3.1. Fc Engineered and Glycoengineered Market for Oncological Disorders, 2024-2035
    • 15.3.2. Fc Engineered and Glycoengineered Market for Dermatological Disorders, 2024-2035
    • 15.3.3. Fc Engineered and Glycoengineered Market for Autoimmune Disorders, 2024-2035
    • 15.3.4. Fc Engineered and Glycoengineered Market for Rare Disorders, 2024-2035
    • 15.3.4. Fc Engineered and Glycoengineered Market for Other Disorders, 2024-2035
  • 15.4. Data Triangulation and Validation

16. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035
    • 16.3.1. Fc Engineered and Glycoengineered Market for Intravenous Route, 2024-2035
    • 16.3.2. Fc Engineered and Glycoengineered Market for Subcutaneous Route, 2024-2035
    • 16.3.3. Fc Engineered and Glycoengineered Market for Intramuscular Route, 2024-2035
  • 16.4. Data Triangulation and Validation

17. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035
    • 17.3.1. Fc Engineered and Glycoengineered Market in North America, 2024-2035
    • 17.3.2. Fc Engineered and Glycoengineered Market in Europe, 2024-2035
    • 17.3.3. Fc Engineered and Glycoengineered Market in Asia-Pacific, 2024-2035
    • 17.3.4. Fc Engineered and Glycoengineered Market in Rest of the World, 2024-2035
  • 17.4. Data Triangulation and Validation

18. Fc ENGINEEREDAND GLYCOENGINEERED ANTIBODIES MARKET,SALES FORECAST OF DRUGS

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Sales Forecast
    • 18.3.1. AK-105 Sales Forecast
    • 18.3.2. BeyfortusTM Sales Forecast
    • 18.3.3. Briumvi(R) Sales Forecast
    • 18.3.4. Fasenra(R) Sales Forecast
    • 18.3.5. Gazyva(R) Sales Forecast
    • 18.3.6. Imfinzi(R) Sales Forecast
    • 18.3.7. Margenza Sales Forecast
    • 18.3.8. Monjuvi(R) Sales Forecast
    • 18.3.9. Ocrevus(R) Sales Forecast
    • 18.3.10. POTELIGEO(R) Sales Forecast
    • 18.3.11. Saphnelo(R) Sales Forecast
    • 18.3.12. Skyrizi(R) Sales Forecast
    • 18.3.13. Soliris(R) Sales Forecast
    • 18.3.14. Tecentriq(R) Sales Forecast
    • 18.3.15. Tislelizumab Sales Forecast
    • 18.3.16. Tzield(R) Sales Forecast
    • 18.3.17. Ultomiris(R) Sales Forecast
    • 18.3.18. Uplizna(R) Sales Forecast
  • 18.4. Phase III Fc Engineered and Glycoengineered Antibodies Market: Sales Forecast
    • 18.4.1. Clazakizumab Sales Forecast
    • 18.4.2. FPA144 Sales Forecast
    • 18.4.3. Skyrizi Sales Forecast
    • 18.4.4. TQ-B2450 Sales Forecast
    • 18.4.5. Visterra Sales Forecast
  • 18.6. Data Triangulation and Validation

19. CONCLUDING REMARKS

  • 19.1. Chapter Overview

20 APPENDIX I: TABULATED DATA

21 APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 1.1. Fc and Glycoengineered Antibodies Market: Report Attribute / Market Segment
  • Table 5.1. Features of Different Isotypes of Antibodies
  • Table 5.2. Features of Engineered Fc Regions
  • Table 6.1. Fc Engineered and Glycoengineered Antibodies: Overall Pipeline
  • Table 6.2. Fc Engineered and Glycoengineered Antibodies: Information on Type of Engineering, Impact of Engineering and Fc Engineering Technology
  • Table 6.3. Fc Engineered and Glycoengineered Antibodies: List of Developers
  • Table 7.1. Fc Engineered and Glycoengineered Antibodies: List of Drug Developers Profiled
  • Table 7.2. AbbVie: Company Snapshot
  • Table 7.3. Drug Profile: Skyrizi
  • Table 7.4. AbbVie: Recent Developments and Future Outlook
  • Table 7.5. Alexion Pharmaceuticals: Company Snapshot
  • Table 7.6. Drug Profile: Soliris
  • Table 7.7. Drug Profile: Ultomiris
  • Table 7.8. AstraZeneca: Company Snapshot
  • Table 7.9. Drug Profile: Beyfortus
  • Table 7.10. Drug Profile: Imfinzi
  • Table 7.11. Drug Profile: Fasenra
  • Table 7.12. Drug Profile: Saphnelo
  • Table 7.13. AstraZeneca: Recent Developments and Future Outlook
  • Table 7.14. Genentech: Company Snapshot
  • Table 7.15. Drug Profile: Gazyva
  • Table 7.16. Drug Profile: Ocrevus
  • Table 7.17. Drug Profile: Tecentriq
  • Table 7.18. Genentech: Recent Developments and Future Outlook
  • Table 7.19. MacroGenics: Company Snapshot
  • Table 7.20. Drug Profile: Margenza
  • Table 7.21. Drug Profile: MGA-271
  • Table 7.22. MacroGenics: Recent Developments and Future Outlook
  • Table 7.23. Kyowa Kirin: Company Snapshot
  • Table 7.24. Drug Profile: POTELIGEO
  • Table 7.25. Kyowa Kirin: Recent Developments and Future Outlook
  • Table 7.26. Akeso Biopharma: Company Snapshot
  • Table 7.27. Drug Profile: Penpulimab
  • Table 7.28. Amgen: Company Snapshot
  • Table 7.29. Drug Profile: Bmarituzumab
  • Table 7.30. Drug Profile: XmAb Antibody
  • Table 7.31. Drug Profile: FPA157
  • Table 7.32. Boehringer Ingelheim: Company Snapshot
  • Table 7.33. Drug Profile: Spesolimab
  • Table 7.34. MorphoSys: Company Snapshot
  • Table 7.35. Drug Profile: Tafasitamab
  • Table 7.36. Xencor: Company Snapshot
  • Table 7.37. Drug Profile: Tidutamab
  • Table 7.38. Drug Profile: XmAb22841
  • Table 7.39. Drug Profile: XmAb23104
  • Table 7.40. Drug Profile: Plamotamab
  • Table 7.41. Drug Profile: Vibecotamab
  • Table 7.42. Drug Profile: RO7310729
  • Table 7.43. Drug Profile: XmAb20717
  • Table 7.44. Drug Profile: XmAb819
  • Table 7.45. Drug Profile: XmAb27564
  • Table 7.46. Drug Profile: VRC01LS
  • Table 9.1. Fc Engineered and Glycoengineered Antibodies: List of Partnerships and Collaborations, 2016-2024
  • Table 9.2. Partnerships and Collaborations: Information on Type of Engineering and Therapeutic Area
  • Table 11.1. Patent Analysis: Top CPC Sections
  • Table 11.2. Patent Analysis: Top CPC Symbols
  • Table 11.3. Patent Analysis: Top CPC Codes
  • Table 11.4. Patent Analysis: Summary of Benchmarking Analysis
  • Table 11.5. Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 11.6. Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 11.7. Patent Portfolio: List of Leading Patents (by Number of Citations)
  • Table 21.1. Fc Engineered and Glycoengineered Antibodies: Distribution by Stage of Development
  • Table 21.2. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Antibody
  • Table 21.3. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Engineering
  • Table 21.4. Fc Engineered and Glycoengineered Antibodies: Distribution by Impact of Engineering
  • Table 21.5. Fc Engineered and Glycoengineered Antibodies: Distribution by Biological Target
  • Table 21.6. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Therapy
  • Table 21.7. Fc Engineered and Glycoengineered Antibodies: Distribution by Target Disease Indication
  • Table 21.8. Fc Engineered and Glycoengineered Antibodies: Distribution by Therapeutic Area
  • Table 21.9. Fc Engineered and Glycoengineered Antibodies: Distribution by Route of Administration
  • Table 21.10. Popular Fc Engineering Technologies: Distribution by Number of Development Programs
  • Table 21.11. Fc Engineered and Glycoengineered Antibodies: Distribution by Year of Establishment
  • Table 21.12. Fc Engineered and Glycoengineered Antibodies: Distribution by Company Size
  • Table 21.13. Fc Engineered and Glycoengineered Antibodies: Distribution by Location of Headquarters
  • Table 21.14. AbbVie: Annual Revenues, FY 2019-FY 2023 (USD Billion)
  • Table 21.15. AstraZeneca: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
  • Table 21.16. Roche (Parent Company of Genentech): Annual Revenues, FY 2019 - FY 2023 (CHF Billion)
  • Table 21.17. MacroGenics: Annual Revenues, FY 2019 - 9M FY 2023 (USD Million)
  • Table 21.18. Kyowa Kirin: Annual Revenues, FY 2019 - FY 2023 (YEN Billion)
  • Table 21.19. Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2015-2024
  • Table 21.20. Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Pre-2015-2024
  • Table 21.21. Clinical Trial Analysis: Distribution by Trial Phase
  • Table 21.22. Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
  • Table 21.23. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2015-2024
  • Table 21.24. Clinical Trial Analysis: Distribution by Trial Status
  • Table 21.25. Clinical Trial Analysis: Distribution by Patient Gender
  • Table 21.26. Clinical Trial Analysis: Distribution by Target Indication
  • Table 21.27. Clinical Trial Analysis: Distribution by Type of Trial Masking
  • Table 21.28. Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Table 21.29. Clinical Trial Analysis: Distribution by Trial Purpose
  • Table 21.30. Clinical Trial Analysis: Distribution by Design Allocation
  • Table 21.31. Leading Industry Players: Distribution by Number of Registered Trials
  • Table 21.32. Leading Non-Industry Players: Distribution by Number of Registered Trials
  • Table 21.33. Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Table 21.34. Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
  • Table 21.35. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2024
  • Table 21.36. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 21.37. Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 21.38. Partnerships and Collaborations: Distribution by Type of Engineering
  • Table 21.39. Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 21.40. Most Active Players: Distribution by Number of Partnerships
  • Table 21.41. Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Table 21.42. Partnerships and Collaborations: Local and International Agreements
  • Table 21.43. Grant Analysis: Cumulative Year-wise Trend, 2019-2024
  • Table 21.44. Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
  • Table 21.45. Grants Analysis: Distribution by Funding Institute Center
  • Table 21.46. Grants Analysis: Distribution by Support Period
  • Table 21.47. Grants Analysis: Distribution by Funding Institute Center and Support Period
  • Table 21.48. Grants Analysis: Distribution by Type of Grant Application
  • Table 21.49. Grants Analysis: Distribution by Purpose of Grant Award
  • Table 21.50. Grants Analysis: Distribution by Activity Code
  • Table 21.51. Grants Analysis: Distribution by Study Section Involved
  • Table 21.52. Most Popular Departments: Distribution by Number of Grants
  • Table 21.53. Prominent Program Officers: Distribution by Number of Grants
  • Table 21.54. Popular Recipient Organizations: Distribution by Number of Grants
  • Table 21.55. Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
  • Table 21.56. Popular Recipient Organizations: Distribution by States in the US
  • Table 21.57. Patent Analysis: Distribution by Type of Patent
  • Table 21.58. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2024
  • Table 21.59. Patent Analysis: Distribution by Patent Application Year, Pre-2019-2023
  • Table 21.60. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
  • Table 21.61. Patent Analysis: Distribution by Patent Jurisdiction
  • Table 21.62. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Table 21.63. Leading Industry Players: Distribution by Number of Patents
  • Table 21.64. Leading Non-Industry Players: Distribution by Number of Patents
  • Table 21.65. Leading Individual Assignees: Distribution by Number of Patents
  • Table 21.66. Patent Analysis: Distribution by Patent Age
  • Table 21.67. Fc Engineered and Glycoengineered Antibodies: Patent Valuation
  • Table 21.68. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 21.69. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Conservative Scenario (USD Billion)
  • Table 21.70. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Optimistic Scenario (USD Billion)
  • Table 21.71. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering, 2024 and 2035 (USD Billion)
  • Table 21.72. Fc Engineered and Glycoengineered Antibodies Market for Fc Engineered Antibodies, 2024-2035 (USD Billion)
  • Table 21.73. Fc Engineered and Glycoengineered Antibodies Market for Glycoengineered Antibodies, 2024-2035 (USD Billion)
  • Table 21.74. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035 (USD Billion)
  • Table 21.75. Fc Engineered and Glycoengineered Antibodies Market for Monotherapy, 2024-2035 (USD Billion)
  • Table 21.75. Fc Engineered and Glycoengineered Antibodies Market for Combination Therapy, 2024-2035 (USD Billion)
  • Table 21.76. Fc Engineered and Glycoengineered Antibodies Market for Both, 2024-2035 (USD Billion)
  • Table 21.77. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035 (USD Billion)
  • Table 21.78. Fc Engineered and Glycoengineered Antibodies Market for Oncological Disorders, 2024-2035 (USD Billion)
  • Table 21.79. Fc Engineered and Glycoengineered Antibodies Market for Dermatological Disorders, 2024-2035 (USD Billion)
  • Table 21.80. Fc Engineered and Glycoengineered Antibodies Market for Autoimmune Disorders, 2024-2035 (USD Billion)
  • Table 21.81. Fc Engineered and Glycoengineered Antibodies Market for Rare Disorders, 2024-2035 (USD Billion)
  • Table 21.82. Fc Engineered and Glycoengineered Antibodies Market for Other Disorders, 2024-2035 (USD Billion)
  • Table 21.83. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035 (USD Billion)
  • Table 21.84. Fc Engineered and Glycoengineered Antibodies Market for Intravenous Route, 2024-2035 (USD Billion)
  • Table 21.85. Fc Engineered and Glycoengineered Antibodies Market for Subcutaneous Route, 2024-2035 (USD Billion)
  • Table 21.86. Fc Engineered and Glycoengineered Antibodies Market for Intramuscular Route, 2024-2035 (USD Billion)
  • Table 21.87. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035 (USD Billion)
  • Table 21.88. Fc Engineered and Glycoengineered Antibodies Market in North America, 2024-2035 (USD Billion)
  • Table 21.89. Fc Engineered and Glycoengineered Antibodies Market in Europe, 2024-2035 (USD Billion)
  • Table 21.90. Fc Engineered and Glycoengineered Antibodies Market in Asia-Pacific, 2024-2035 (USD Billion)
  • Table 21.91. Fc Engineered and Glycoengineered Antibodies Market in Rest of the World, 2024-2035 (USD Billion)
  • Table 21.92. Commercialized Fc Engineered and Glycoengineered Antibodies Market: AK-105 Sales Forecast, 2021-2035 (USD Billion)
  • Table 21.93. Commercialized Fc Engineered and Glycoengineered Antibodies Market: BeyfortusTM Sales Forecast, 2022-2035 (USD Billion)
  • Table 21.94. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Briumvi(R) Sales Forecast, 2023-2035 (USD Billion)
  • Table 21.95. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Fasenra(R) Sales Forecast, 2018-2035 (USD Billion)
  • Table 21.96. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Gazyva(R) Sales Forecast, 2017-2035 (USD Billion)
  • Table 21.97. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Imfinzi(R) Sales Forecast, 2018-2035 (USD Billion)
  • Table 21.98. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Margenza Sales Forecast, 2021-2035 (USD Billion)
  • Table 21.99. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Monjuvi(R) Sales Forecast, 2020-2035 (USD Billion)
  • Table 21.100. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ocrevus(R) Sales Forecast, 2017-2035 (USD Billion)
  • Table 21.101. Commercialized Fc Engineered and Glycoengineered Antibodies Market: POTELIGEO(R) Sales Forecast, 2019-2035 (USD Billion)
  • Table 21.102. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Saphnelo(R) Sales Forecast, 2021-2035 (USD Billion)
  • Table 21.103. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Skyrizi(R) Sales Forecast, 2020-2035 (USD Billion)
  • Table 21.104. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Soliris(R) Sales Forecast, 2017-2035 (USD Billion)
  • Table 21.105. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tecentriq(R) Sales Forecast, 2017-2035 (USD Billion)
  • Table 21.106. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tislelizumab Sales Forecast, 2020-2035 (USD Billion)
  • Table 21.107. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tzield(R) Sales Forecast, 2023-2035 (USD Billion)
  • Table 21.108. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ultomiris(R) Sales Forecast, 2019-2035 (USD Billion)
  • Table 21.109. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Uplizna(R) Sales Forecast, 2020-2035 (USD Billion)
  • Table 21.110. Phase III Fc Engineered and Glycoengineered Antibodies Market: Clazakizumab Sales Forecast, 2030-2035 (USD Billion)
  • Table 21.111. Phase III Fc Engineered and Glycoengineered Antibodies Market: FPA144 Sales Forecast, 2027-2035 (USD Billion)
  • Table 21.112. Phase III Fc Engineered and Glycoengineered Antibodies Market: Skyrizi Sales Forecast, 2024-2035 (USD Billion)
  • Table 21.113. Phase III Fc Engineered and Glycoengineered Antibodies Market: TQ-B2450 Sales Forecast, 2027-2035 (USD Billion)
  • Table 21.114. Phase III Fc Engineered and Glycoengineered Antibodies Market: VIS649 Sales Forecast, 2028-2035 (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentation
  • Figure 3.1. Lessons Learnt from Past Recessions
  • Figure 4.1. Executive Summary: Overall Market Landscape
  • Figure 4.2. Executive Summary: Clinical Trial Analysis
  • Figure 4.3. Executive Summary: Partnerships and Collaborations
  • Figure 4.4. Executive Summary: Grant Analysis
  • Figure 4.5. Executive Summary: Patent Analysis
  • Figure 4.6. Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 5.1. Structure of an Antibody
  • Figure 5.2. Historical Timeline of Antibody Development
  • Figure 5.3. Main Functions of Antibodies
  • Figure 6.1. Fc Engineered and Glycoengineered Antibodies: Distribution by Stage of Development
  • Figure 6.2. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Antibody
  • Figure 6.3. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Engineering
  • Figure 6.4. Fc Engineered and Glycoengineered Antibodies: Distribution by Impact of Engineering
  • Figure 6.5. Fc Engineered and Glycoengineered Antibodies: Distribution by Biological Target
  • Figure 6.6. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Therapy
  • Figure 6.7. Fc Engineered and Glycoengineered Antibodies: Distribution by Target Disease Indication
  • Figure 6.8. Fc Engineered and Glycoengineered Antibodies: Distribution by Therapeutic Area
  • Figure 6.9. Fc Engineered and Glycoengineered Antibodies: Distribution by Route of Administration
  • Figure 6.10. Popular Fc Engineered Technologies: Distribution by Number of Marketed Drugs Development Programs
  • Figure 6.11. Fc Engineered and Glycoengineered Antibodies: Distribution by Year of Establishment
  • Figure 6.12. Fc Engineered and Glycoengineered Antibodies: Distribution by Company Size
  • Figure 6.13. Fc Engineered and Glycoengineered Antibodies: Distribution by Location of Headquarters
  • Figure 6.14. World Map Representation: Analysis by Geography
  • Figure 6.15. Leading Developers: Distribution by Number of Drugs
  • Figure 7.1. AbbVie: Annual Revenues, FY 2019-FY 2023 (USD Billion)
  • Figure 7.2. AstraZeneca: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
  • Figure 7.3. Roche (Parent Company of Genentech): Annual Revenues, FY 2019 - FY 2023 (CHF Billion)
  • Figure 7.4. MacroGenics: Annual Revenues, FY 2019 - 9M FY 2023 (USD Million)
  • Figure 7.5. Kyowa Kirin: Annual Revenues, FY 2019 - FY 2023 (YEN Billion)
  • Figure 8.1. Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2015-2024
  • Figure 8.2. Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Pre-2015-2024
  • Figure 8.3. Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 8.4. Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
  • Figure 8.5. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2015-2024
  • Figure 8.6. Clinical Trial Analysis: Distribution by Trial Status
  • Figure 8.7. Clinical Trial Analysis: Distribution by Patient Gender
  • Figure 8.8. Clinical Trial Analysis: Distribution by Target Indication
  • Figure 8.9. Clinical Trial Analysis: Distribution by Type of Trial Masking
  • Figure 8.10. Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Figure 8.11. Clinical Trial Analysis: Distribution by Trial Purpose
  • Figure 8.12. Clinical Trial Analysis: Distribution by Design Allocation
  • Figure 8.13. Leading Industry Players: Distribution by Number of Registered Trials
  • Figure 8.14. Leading Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 8.15. Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Figure 8.16. Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
  • Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2024
  • Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 9.4. Partnerships and Collaborations: Distribution by Type of Engineering
  • Figure 9.5. Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 9.6. Most Active Players: Distribution by Number of Partnerships
  • Figure 9.7. Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 9.8. Partnerships and Collaborations: Local and International Agreements
  • Figure 10.1. Grant Analysis: Cumulative Year-wise Trend, 2019-2024
  • Figure 10.2. Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
  • Figure 10.3. Grants Analysis: Distribution by Funding Institute Center
  • Figure 10.4. Grants Analysis: Distribution by Support Period
  • Figure 10.5. Grants Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 10.6. Grants Analysis: Distribution by Type of Grant Application
  • Figure 10.7. Grants Analysis: Distribution by Purpose of Grant Award
  • Figure 10.8. Grants Analysis: Distribution by Activity Code
  • Figure 10.9. Grants Analysis: Distribution by Study Section Involved
  • Figure 10.10. Most Popular Departments: Distribution by Number of Grants
  • Figure 10.11. Prominent Program Officers: Distribution by Number of Grants
  • Figure 10.12. Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 10.13. Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
  • Figure 10.14. Popular Recipient Organizations: Distribution by States in the US
  • Figure 11.1. Patent Analysis: Distribution by Type of Patent
  • Figure 11.2. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2024
  • Figure 11.3. Patent Analysis: Distribution by Patent Application Year, Pre-2019-2023
  • Figure 11.4. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
  • Figure 11.5. Patent Analysis: Distribution by Patent Jurisdiction
  • Figure 11.6. Patent Analysis: Distribution by CPC Symbols
  • Figure 11.7. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Figure 11.8. Leading Industry Players: Distribution by Number of Patents
  • Figure 11.9. Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 11.10. Leading Individual Assignees: Distribution by Number of Patents
  • Figure 11.11. Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Figure 11.12. Patent Benchmarking Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
  • Figure 11.13. Patent Analysis: Distribution by Patent Age
  • Figure 11.14. Fc Engineered and Glycoengineered Antibodies: Patent Valuation
  • Figure 12.1. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 12.2. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Conservative Scenario (USD Billion)
  • Figure 12.3. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Optimistic Scenario (USD Billion)
  • Figure 13.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering,2024 and 2035
  • Figure 13.2. Fc Engineered and Glycoengineered Antibodies Market for Fc Engineered Antibodies, 2024-2035 (USD Billion)
  • Figure 13.3. Fc Engineered and Glycoengineered Antibodies Market for Glycoengineered Antibodies, 2024-2035 (USD Billion)
  • Figure 14.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035
  • Figure 14.2. Fc Engineered and Glycoengineered Antibodies Market for Monotherapy, 2024-2035 (USD Billion)
  • Figure 14.3. Fc Engineered and Glycoengineered Antibodies Market for Combination Therapy, 2024-2035 (USD Billion)
  • Figure 14.4. Fc Engineered and Glycoengineered Antibodies Market for Both, 2024-2035 (USD Billion)
  • Figure 15.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035
  • Figure 15.2. Fc Engineered and Glycoengineered Antibodies Market for Oncological Disorders, 2024-2035 (USD Billion)
  • Figure 15.3. Fc Engineered and Glycoengineered Antibodies Market for Dermatological Disorders, 2024-2035 (USD Billion)
  • Figure 15.4. Fc Engineered and Glycoengineered Antibodies Market for Autoimmune Disorders, 2024-2035 (USD Billion)
  • Figure 15.5. Fc Engineered and Glycoengineered Antibodies Market for Rare Disorders, 2024-2035 (USD Billion)
  • Figure 15.6. Fc Engineered and Glycoengineered Antibodies Market for Other Disorders, 2024-2035 (USD Billion)
  • Figure 16.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035
  • Figure 16.2. Fc Engineered and Glycoengineered Antibodies Market for Intravenous Route, 2024-2035 (USD Billion)
  • Figure 16.3. Fc Engineered and Glycoengineered Antibodies Market for Subcutaneous Route, 2024-2035 (USD Billion)
  • Figure 16.4. Fc Engineered and Glycoengineered Antibodies Market for Intramuscular Route, 2024-2035 (USD Billion)
  • Figure 17.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035
  • Figure 17.2. Fc Engineered and Glycoengineered Antibodies Market in North America, 2024-2035 (USD Billion)
  • Figure 17.3. Fc Engineered and Glycoengineered Antibodies Market in Europe, 2024-2035 (USD Billion)
  • Figure 17.4. Fc Engineered and Glycoengineered Antibodies Market in Asia-Pacific, 2024-2035 (USD Billion)
  • Figure 17.5. Fc Engineered and Glycoengineered Antibodies Market in Rest of the World, 2024-2035 (USD Billion)
  • Figure 18.1. Commercialized Fc Engineered and Glycoengineered Antibodies Market: AK-105 Sales Forecast, 2021-2035 (USD Billion)
  • Figure 18.2. Commercialized Fc Engineered and Glycoengineered Antibodies Market: BeyfortusTM Sales Forecast, 2022-2035 (USD Billion)
  • Figure 18.3. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Briumvi(R) Sales Forecast, 2023-2035 (USD Billion)
  • Figure 18.4. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Fasenra(R) Sales Forecast, 2018-2035 (USD Billion)
  • Figure 18.5. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Gazyva(R) Sales Forecast, 2017-2035 (USD Billion)
  • Figure 18.6. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Imfinzi(R) Sales Forecast, 2018-2035 (USD Billion)
  • Figure 18.7. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Margenza Sales Forecast, 2021-2035 (USD Billion)
  • Figure 18.8. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Monjuvi(R) Sales Forecast, 2020-2035 (USD Billion)
  • Figure 18.9. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ocrevus(R) Sales Forecast, 2017-2035 (USD Billion)
  • Figure 18.10. Commercialized Fc Engineered and Glycoengineered Antibodies Market: POTELIGEO(R) Sales Forecast, 2019-2035 (USD Billion)
  • Figure 18.11. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Saphnelo(R) Sales Forecast, 2021-2035 (USD Billion)
  • Figure 18.12. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Skyrizi(R) Sales Forecast, 2020-2035 (USD Billion)
  • Figure 18.13. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Soliris(R) Sales Forecast, 2017-2035 (USD Billion)
  • Figure 18.14. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tecentriq(R) Sales Forecast, 2017-2035 (USD Billion)
  • Figure 18.15. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tislelizumab Sales Forecast, 2020-2035 (USD Billion)
  • Figure 18.16. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tzield(R) Sales Forecast, 2023-2035 (USD Billion)
  • Figure 18.17. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ultomiris(R) Sales Forecast, 2019-2035 (USD Billion)
  • Figure 18.18. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Uplizna(R) Sales Forecast, 2020-2035 (USD Billion)
  • Figure 18.19. Phase III Fc Engineered and Glycoengineered Antibodies Market: Clazakizumab Sales Forecast, 2030-2035 (USD Billion)
  • Figure 18.20. Phase III Fc Engineered and Glycoengineered Antibodies Market: FPA144 Sales Forecast, 2027-2035 (USD Billion)
  • Figure 18.21. Phase III Fc Engineered and Glycoengineered Antibodies Market: Skyrizi Sales Forecast, 2024-2035 (USD Billion)
  • Figure 18.22. Phase III Fc Engineered and Glycoengineered Antibodies Market: TQ-B2450 Sales Forecast, 2027-2035 (USD Billion)
  • Figure 18.23. Phase III Fc Engineered and Glycoengineered Antibodies Market: VIS649 Sales Forecast, 2028-2035 (USD Billion)
  • Figure 19.1. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Overall Market Landscape
  • Figure 19.2. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Clinical Trial Analysis
  • Figure 19.3. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Partnerships and Collaborations
  • Figure 19.4. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Grant Analysis
  • Figure 19.5. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Patent Analysis
  • Figure 19.6. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Market Sizing and Opportunity Analysis (I/II)
  • Figure 19.7. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Market Sizing and Opportunity Analysis (II/II)